Diverse Neurological Effects Linked to Anti-PD-1 Therapy

Share this content:
Diverse Neurological Effects Linked to Anti-PD-1 Therapy
Diverse Neurological Effects Linked to Anti-PD-1 Therapy

MONDAY, Sept. 11, 2017 (HealthDay News) -- Neurological complications associated with anti-programmed death 1 (PD-1) antibody treatment have a diverse phenotype, according to a study published online Sept. 5 in JAMA Neurology.

Justin C. Kao, M.B.Ch.B., from the Mayo Clinic in Rochester, Minnesota, and colleagues conducted a retrospective cohort study involving patients with development of neurological symptoms within 12 months of receiving anti-PD-1 therapy.

The researchers found that 2.9 percent of the 347 patients treated with anti-PD-1 monoclonal antibodies developed subacute onset of neurological complications. Seven of these patients received pembrolizumab and three nivolumab. Neurological complications occurred after a median of 5.5 anti-PD-1 inhibitor cycles. Myopathy, varied neuropathies, cerebellar ataxia, autoimmune retinopathy, bilateral internuclear ophthalmoplegia, and headache were reported complications. Reported peripheral neuropathies were axonal and demyelinating polyradiculoneuropathies, length-dependent neuropathies, and asymmetric vasculitic neuropathy.

"Neurological adverse events associated with anti-PD-1 therapy have a diverse phenotype, with more frequent neuromuscular complications," the authors write. "Prompt recognition and discontinuation of anti-PD-1 therapy is recommended. In some cases, immune rescue treatment may be required."

One author disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text
Editorial

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

Amount of Opioids Prescribed After Hospital Discharge Varies

Amount of Opioids Prescribed After Hospital Discharge Varies

45.6 percent of patients using no opioids 24 hours predischarge were prescribed opioids at discharge

Observation Care Cost Saving in Commercially-Insured Patients

Observation Care Cost Saving in Commercially-Insured Patients

Total, out-of-pocket spending considerably lower for observation care; both increased from '09 to '13

Disrupted Sleep Linked to Increased Amyloid- Production

Disrupted Sleep Linked to Increased Amyloid-β Production

Sleep deprivation tied to increased overnight amyloid-β-38, -40, -42 levels by 25 to 30 percent

is free, fast, and customized just for you!

Already a member?

Sign In Now »